Faculty

Norbert Pardi, PhD

Assistant Professor of Microbiology

Department: Microbiology

Graduate Group Affiliations

Contact information

476A Stemmler Hall
Philadelphia, PA 19104

Office: 215 746 6552

Email:
pnorbert@pennmedicine.upenn.edu

Education:
MSc (Biochemistry and Genetics)
University of Szeged, Hungary, 2004.
PhD (Biochemistry and Genetics)
University of Szeged, Hungary, 2011.

Links
Lab Website

Permanent link

> Perelman School of Medicine > Faculty > Details

Description of Research Expertise

mRNA therapeutics

Selected Publications

Fumagalli V, Ravà M, Marotta D, Di Lucia P, Bono EB, Giustini L, De Leo F, Casalgrandi M, Monteleone E, Mouro V, Malpighi C, Perucchini C, Grillo M, De Palma S, Donnici L, Marchese S, Conti M, Muramatsu H, Perlman S, Pardi N, Kuka M, De Francesco R, Bianchi ME, Guidotti LG, Iannacone M.: Antibody-independent protection against heterologous SARS-CoV-2 challenge conferred by prior infection or vaccination. Nat Immunol. Mar 2024.

Weber Y, Böck D, Ivașcu A, Mathis N, Rothgangl T, Ioannidi EI, Blaudt AC, Tidecks L, Vadovics M, Muramatsu H, Reichmuth A, Marquart KF, Kissling L, Pardi N, Jinek M, Schwank G.: Enhancing prime editor activity by directed protein evolution in yeast. Nat Commun 15(1): 2092, Mar 2024.

Ábrahám E, Bajusz C, Marton A, Borics A, Mdluli T, Pardi N*, Lipinszki Z.: Expression and purification of the receptor-binding domain of SARS-CoV-2 spike protein in mammalian cells for immunological assays. FEBS Open Bio 14(3): 380-389, Mar 2024.

Wang HY, Li L, Nelson CS, Barfield R, Valencia S, Chan C, Muramatsu H, Lin PJC, Pardi N, An Z, Weissman D, Permar SR.: Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth. NPJ Vaccines 9(1): 38, Feb 2024.

Matias J, Cui Y, Lynn GE, DePonte K, Mesquita E, Muramatsu H, Alameh MG, Dwivedi G, Tam YK, Pardi N, Weissman D, Fikrig E.: mRNA vaccination of rabbits alters the fecundity, but not the attachment, of adult Ixodes scapularis. Sci Rep 14(1): 496, Jan 2024.

Kunkeaw N, Nguitragool W, Takashima E, Kangwanrangsan N, Muramatsu H, Tachibana M, Ishino T, Lin PJC, Tam YK, Pichyangkul S, Tsuboi T, Pardi N*, Sattabongkot J.: A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax. NPJ Vaccines 8(1): 187, Dec 2023.

Rizvi F, Lee YR, Diaz-Aragon R, Bawa PS, So J, Florentino RM, Wu S, Sarjoo A, Truong E, Smith AR, Wang F, Everton E, Ostrowska A, Jung K, Tam Y, Muramatsu H, Pardi N, Weissman D, Soto-Gutierrez A, Shin D, Gouon-Evans V.: VEGFA mRNA-LNP promotes biliary epithelial cell-to-hepatocyte conversion in acute and chronic liver diseases and reverses steatosis and fibrosis. Cell Stem Cell 30(12): 1640-1657, Dec 2023.

Hogan MJ, Maheshwari N, Begg BE, Nicastri A, Hedgepeth EJ, Muramatsu H, Pardi N, Miller MA, Reilly SP, Brossay L, Lynch KW, Ternette N, Eisenlohr LC: Cryptic MHC-E epitope from influenza elicits a potent cytolytic T cell response. Nat Immunol. 11(24): 1933-1946, Nov 2023.

Zhang L, More KR, Ojha A, Jackson CB, Quinlan BD, Li H, He W, Farzan M, Pardi N, Choe H.: Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability. NPJ Vaccines 1(8): 156, Oct 2023.

Pine M, Arora G, Hart TM, Bettini E, Gaudette BT, Muramatsu H, Tombácz I, Kambayashi T, Tam YK, Brisson D, Allman D, Locci M, Weissman D, Fikrig E, Pardi N.* *corresponding author: Development of an mRNA-lipid nanoparticle vaccine against Lyme disease. Mol Ther 9(31): 2702-2714, Sep 2023.